A big F*ck you to the field force

Discussion in 'Sage Therapeutics' started by anonymous, Feb 14, 2020 at 10:50 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Hope we are going to Orlando. I plan to have the family fly in of Friday and spend the next week visiting the parks.
     

  2. anonymous

    anonymous Guest

    I was wondering the same. I get it.
     
  3. anonymous

    anonymous Guest

    this is hysterical. There is no meeting and definitely not in Orlando. In fact there are no live meetings taking place at all.
     
  4. anonymous

    anonymous Guest

    If you had a family you wouldn’t be acting like this. Do you / have you lived there, troll?
     
  5. anonymous

    anonymous Guest

    That is not what my friend in Cambridge tells me. The contract for The Swan Hotel has been signed!! Go post elsewhere troll.
     
  6. anonymous

    anonymous Guest

    We will know March 9, it’s looking less likely given uptick/expansion of COVID-19.
     
  7. anonymous

    anonymous Guest

    Hahah the Swan. What a joke. There is no meeting. No contract. Not at that hotel. And not magical date of March 9. But keeping believing the BS.
     
  8. anonymous

    anonymous Guest

    Less than one month notice. Lame. Also, as a side note, most real companies give an annual calendar that includes BONUS PAYOUT DATES and meetings.
     
  9. anonymous

    anonymous Guest

    Not a sage decision!!
     
  10. anonymous

    anonymous Guest

    What is the latest on March 9th? The financial call this week will be a ball buster. Does Matt B know how to address the field? Not a peep out of that man. Talk about no leadership skills. Where do they get these people? What are his credentials?
     
  11. anonymous

    anonymous Guest

     
  12. anonymous

    anonymous Guest

    The problem is not the selling of the product. Zulresso is a very good product. The problem is there is no route of reimbursement for the SOCs and Sage does not have a strategy for this. More than 1/2 of the births in the USA have Medicaid and Sage does not have a plan nor a strategy for the hospitals/treatment centers to figure out what they will get paid for. Do you know that the majority of Medicaid does not recognize a C-code for reimbursement. A generic J-code has no visibility for what will actually get paid to these SOCs that voluntarily take this into their hospital/treatment center. So would you if you were the CFO of a hospital electively buy a very expensive product like Zulresso when you have no idea what your reimbursement will be for the drug. I don't think so. That doesn't even consider the hospital stay. This is not a sales problem with a lack of sales people that can sell, this is a company wide issue that no one at Sage discusses. The real problem is this finger pointing on what department to hold responsible for this failed launch. Everyone needs to come together and spend their energy on the solution but unfortunately I don't see that happening. Time is not going to solve this.
     
  13. anonymous

    anonymous Guest

    This is dead on. I’d like to also add that additionally a huge issue with Zulresso is this wack ass way of enrollment to sites of care. Most sites of care have no interest in processing extremely lengthy prior authorizations for this product and stay for a patient and the drs office in the community aren’t set up to do this well either. Now multiply this issue by a million plans with a million different pieces of restrictions and criteria and you have an impasse.
     
  14. anonymous

    anonymous Guest

    What % of the remaining sales force do they “need” to keep?
     
  15. anonymous

    anonymous Guest

    This is accurate but I think people are missing the big picture of what went wrong here. Zulresso was not designed for PPD. Zulresso was designed for a multi-day hospital stay for comatose patients in SRSE. It was designed for multiple day infusion, multiple reformulation and bag changes per day, and to cause sedation. PPD was a backup plan in case SRSE failed. SRSE did fail, and Sage tried to get around this by positioning Zulresso for PPD broadly in the home setting. The issue was that Zulresso was studied in an inpatient setting and not in the home. If you paid any attention to prior company statements, the company spoke on the home infusion plan. If you followed the Advisory Committee meeting, the FDA squashed the home care market due to sedation and safety fears. Then Sage had to reposition to the hospital setting which would be more severe patients, a much smaller patient population that would require a much higher price for the product. Then we all know about the issues with reimbursement and price for this setting and patient population. The company has made numerous mistakes over the years and has sold the promise but reality is now catching up.
     
  16. anonymous

    anonymous Guest

    Less than 50%. Ideally it should be a very small sales force of only 6-8 districts and 40-50 person sales force.
     
  17. anonymous

    anonymous Guest

    Enlightening post. Thank you!
     
  18. anonymous

    anonymous Guest

    Thanks for this educational post! Looks like they made a lot of mistakes indeed. Sad.